A randomized trial of bevacizumab for newly diagnosed glioblastoma
MR Gilbert, JJ Dignam, TS Armstrong… - … England Journal of …, 2014 - Mass Medical Soc
Background Concurrent treatment with temozolomide and radiotherapy followed by
maintenance temozolomide is the standard of care for patients with newly diagnosed …
maintenance temozolomide is the standard of care for patients with newly diagnosed …
Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma
Background Standard therapy for newly diagnosed glioblastoma is radiotherapy plus
temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab …
temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab …
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
OL Chinot, T de La Motte Rouge, N Moore, A Zeaiter… - Advances in …, 2011 - Springer
Despite treatment with the current standard-of-care therapies, patients with newly diagnosed
glioblastoma multiforme (GBM) exhibit dismal prognoses. Bevacizumab has demonstrated …
glioblastoma multiforme (GBM) exhibit dismal prognoses. Bevacizumab has demonstrated …
A randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma
AA Brandes, M Gil‐Gil, F Saran, AF Carpentier… - The …, 2019 - academic.oup.com
Background We assessed the efficacy and safety of bevacizumab (BEV) through multiple
lines in patients with recurrent glioblastoma who had progressed after first‐line treatment …
lines in patients with recurrent glioblastoma who had progressed after first‐line treatment …
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed …
JJ Vredenburgh, A Desjardins, DA Reardon… - Clinical Cancer …, 2011 - AACR
Purpose: To determine if the addition of bevacizumab to radiation therapy and
temozolomide, followed by bevacizumab, temozolomide, and irinotecan, for newly …
temozolomide, followed by bevacizumab, temozolomide, and irinotecan, for newly …
Glioblastoma and other malignant gliomas: a clinical review
A Omuro, LM DeAngelis - Jama, 2013 - jamanetwork.com
Importance Glioblastomas and malignant gliomas are the most common primary malignant
brain tumors, with an annual incidence of 5.26 per 100 000 population or 17 000 new …
brain tumors, with an annual incidence of 5.26 per 100 000 population or 17 000 new …
RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).
MR Gilbert, J Dignam, M Won, DT Blumenthal… - 2013 - ascopubs.org
1 Background: Chemoradiation (CRT) with temozolomide (TMZ/RT→ TMZ) is the standard of
care for newly diagnosed GBM. This trial determined if the addition of Bev to standard CRT …
care for newly diagnosed GBM. This trial determined if the addition of Bev to standard CRT …
The role of bevacizumab in the treatment of glioblastoma
RJ Diaz, S Ali, MG Qadir, MI De La Fuente… - Journal of neuro …, 2017 - Springer
Bevacizumab has been used in patients with GBM as a salvage therapy since its approval in
the United States for recurrent GBM in 2009. In order to review the therapeutic effect of …
the United States for recurrent GBM in 2009. In order to review the therapeutic effect of …
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme
Purpose This open-label, prospective, multicenter single-arm phase II study combined
bevacizumab (BV) with radiation therapy (RT) and temozolomide (TMZ) for the treatment of …
bevacizumab (BV) with radiation therapy (RT) and temozolomide (TMZ) for the treatment of …
[HTML][HTML] Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine
KJ Wenger, M Wagner, SJ You, K Franz… - Oncology …, 2017 - spandidos-publications.com
In previous trials, bevacizumab failed to prolong the overall survival time in newly diagnosed
glioblastoma and at the first recurrence. Randomized clinical trials at the second or further …
glioblastoma and at the first recurrence. Randomized clinical trials at the second or further …